N-Arachidonoyl Dopamine : A Novel Endocannabinoid and Endovanilloid with Widespread Physiological and Pharmacological Activities Urszula Grabiec and Faramarz Dehghani Cannabis and Cannabinoid Research, 2017, 2, (1), 183-196 DOI: 10.1089/can.2017.0015 Abstract N-arachidonoyl dopamine (NADA) is a member of the family of endocannabinoids to which several other N-acyldopamines belong as well. Their activity is mediated through various targets that include cannabinoid receptors or transient receptor potential vanilloid (TRPV)1. Synthesis and degradation of NADA are not yet fully understood. Nonetheless, there is evidence that NADA plays an important role in nociception and inflammation in the central and peripheral nervous system. The TRPV1 receptor, for which NADA is a [...]
Lire la suiteCannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis : A role for A2A receptors M. Mecha, A. Feliú, P.M. Iñigo, L. Mestre, F.J. Carrillo-Salinas, C. Guaza Neurobiology of Disease, 2013, 59, 141–150 https://doi.org/10.1016/j.nbd.2013.06.016 Inflammation in the central nervous system (CNS) is a complex process that involves a multitude of mole-cules and effectors, and it requires the transmigration of blood leukocytes across the blood–brain barrier(BBB) and the activation of resident immune cells. Cannabidiol (CBD), a non-psychotropic cannabinoid constituent of Cannabis sativa, has potent anti-inflammatory and immunosuppressive properties. Yet, how this compound modifies the deleterious effects of [...]
Lire la suiteImproved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, Xu-Feng Huang and Katrina Weston-Green Neuropsychopharmacology, 2017, 42, 1447–1457 0893-133X/17 www.neuropsychopharmacology.org doi:10.1038/npp.2017.40 Neuropsychiatric disorders such as schizophrenia are associated with cognitive impairment, including learning, memory and attention deficits. Antipsychotic drugs are limited in their efficacy to improve cognition; therefore, new therapeutic agents are required. Cannabidiol (CBD), the non-intoxicating component of cannabis, has anti-inflammatory, neuroprotective and antipsychotic-like properties; however, its ability to improve the cognitive deficits of schizophrenia remains unclear. Using a prenatal infection model, we examined the effect of chronic CBD [...]
Lire la suitePurified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis S. GIACOPPO, T. SOUNDARA RAJAN, M. GALUPPO, F. POLLASTRO, G. GRASSI, P. BRAMANTI, E. MAZZON European Review for Medical and Pharmacological Sciences, 2015, 19, 4906-4919. Abstract. – OBJECTIVE : Multiple Sclerosis (MS) is a global concern disease leading to a progressive, chronic and demyelinating condition, affecting the central nervous system (CNS). The pathology has an inflammatory/autoimmune origin; nevertheless, neuronal cell death mechanisms are not to be underestimated. The present study was designed to test the effects of intraperitoneal administration of cannabidiol (CBD), the main non-psychotropic cannabinoid of [...]
Lire la suiteCannabis sativa L. and Nonpsychoactive Cannabinoids : Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer Federica Pellati, Vittoria Borgonetti, Virginia Brighenti, Marco Biagi, Stefania Benvenuti, and Lorenzo Corsi Hindawi, BioMed Research International, 2018, Volume 2018, Article ID 1691428, 15 pages https://doi.org/10.1155/2018/1691428 Abstract In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L., such as Δ9- tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and their effects on inflammation and cancer-related pain.The National Cancer Institute (NCI) currently recognizes medicinal C. sativa as an effective treatment for providing relief in a number of symptoms associatedwith cancer, including pain, [...]
Lire la suiteCannabinoïds and cancer: causation, remediation, and palliation Wayne Hall, MacDonald Christie, David Currow Lancet Oncology, 2005, 6, 35–42 http://oncology.thelancet.com This review discusses three different associations between cannabinoids and cancer. First, it assesses evidence that smoking of cannabis preparations may cause cancers of the aerodigestive and respiratory system. There have been case reports of upper-respiratory-tract cancers in young adults who smoke cannabis, but evidence from a few epidemiological cohort studies and case-control studies is inconsistent. Second, there is mixed evidence on the effects of THC and other cannabinoids on cancers: in some in vitro and in vivo studies THC and some synthetic cannabinoids have had [...]
Lire la suiteCannabis à usage médical : la France saura-t-elle combler son retard ? Bertrand Lebeau Leibovici Médecin addictologue Membre fondateur du GRECC Juin 2019 Agnès Buzin réussira-t-elle là où Bernard Kouchner puis Marisole Touraine ont échoué ? En queue de peloton européen sur la question de l’accès au cannabis à usage thérapeutique, la France, reconnait l’actuelle ministre de la Santé, a pris du « retard ». Pour le rattraper, elle a demandé à l’Agence Nationale de Sécurité du Médicament (ANSM) de créer un Comité Scientifique Spécialisé Temporaire (CSST) présidé par le professeur Nicolas Authier, qui dirige aussi la Commission des Stupéfiants et Psychotropes, dans le cadre de l’ANSM. L’enfant chéri de l’Agence a [...]
Lire la suiteTherapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain Julia De Ternay, Mickaël Naassila Mikail Nourredine, Alexandre Louvet, François Bailly, Guillaume Sescousse, Pierre Maurage, Olivier Cottencin, Patrizia Maria Carrieri and Benjamin Rolland Frontiers in Pharmacology, 2019, Volume 10, Article 627 doi : 10.3389/fphar.2019.00627 Abstract Background : Cannabidiol (CBD) is a natural component of cannabis that possesses a widespread and complex immunomodulatory, antioxidant, anxiolytic, and antiepileptic properties. Much experimental data suggest that CBD could be used for various purposes in alcohol use disorder (AUD) and alcohol-related damage on the brain and the liver. Aim : To provide a rationale for [...]
Lire la suiteMedical Cannabis and Cannabinoids : An Option for the Treatment of Inflammatory Bowel Disease and Cancer of the Colon? Magdalena Grill, Carina Hasenoehrl, Martin Storr, Rudolf Schicho Medical Cannabis and Cannabinoids, 2018, 1, 28–35 © 2018 The Author(s) Published by S. Karger AG, Basel E-Mail karger@karger.com www.karger.com/mca DOI: 10.1159/000489036 Abstract : In the past few years, we have witnessed a surge of new reports dealing with the role of cannabinoids, synthetic as well as herbal, in the mechanisms of inflammation and carcinogenesis. However, despite the wealth of in vitro data and anecdotal reports, evidence that cannabinoids could act as beneficial drugs in inflammatory bowel disease (IBD) or in [...]
Lire la suiteReview article : The endocannabinoid system and its therapeutic exploitation in multiple sclerosis : Clues for other neuroinflammatory diseases Valerio Chiurchiù, Mario van der Stelt, Diego Centonzed, Mauro Maccarrone, Progress in Neurobiology, 2018, 160 , 82–100 © 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). A B S T R A C T Multiple sclerosis is the most common inflammatory demyelinating disease of the central nervous system, caused by an autoimmune response against myelin that eventually leads to progressive neurodegeneration and disability. Although the knowledge on its underlying neurobiological mechanisms has considerably improved, there is a [...]
Lire la suite